{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:31:50Z","timestamp":1789122710055,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41409-026-02943-9","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:58:27Z","timestamp":1782147507000},"page":"1162-1168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010\u20132020"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5176-1761","authenticated-orcid":false,"given":"Ben","family":"Lerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-5579","authenticated-orcid":false,"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6746","authenticated-orcid":false,"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-2886","authenticated-orcid":false,"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-2374","authenticated-orcid":false,"given":"Andrew","family":"Kin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-394X","authenticated-orcid":false,"given":"Hila","family":"Magen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Shkury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Sarubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2943_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324:79\u201389.","journal-title":"JAMA"},{"key":"2943_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","volume":"390","author":"V Sanchorawala","year":"2024","unstructured":"Sanchorawala V. Systemic light chain amyloidosis. N Engl J Med. 2024;390:2295\u2013307.","journal-title":"N Engl J Med"},{"key":"2943_CR3","doi-asserted-by":"crossref","unstructured":"Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, et al. Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update. Mayo Clin Proc 2021;96:1546\u201377.","DOI":"10.1016\/j.mayocp.2021.03.012"},{"key":"2943_CR4","first-page":"68","volume":"78","author":"I Majolino","year":"1993","unstructured":"Majolino I, Marceno R, Pecoraro G, Scime R, Vasta S, Liberti G, et al. High-dose therapy and autologous transplantation in amyloidosis-AL. Haematologica. 1993;78:68\u201371.","journal-title":"Haematologica"},{"key":"2943_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41409-018-0284-4","volume":"54","author":"C Varga","year":"2019","unstructured":"Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transpl. 2019;54:508\u201318.","journal-title":"Bone Marrow Transpl"},{"key":"2943_CR6","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","volume":"136","author":"G Palladini","year":"2020","unstructured":"Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136:2620\u20137.","journal-title":"Blood"},{"key":"2943_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","volume":"30","author":"AD Wechalekar","year":"2023","unstructured":"Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023;30:3\u201317.","journal-title":"Amyloid"},{"key":"2943_CR8","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111\u20139.","journal-title":"Blood"},{"key":"2943_CR9","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","volume":"103","author":"G Palladini","year":"2004","unstructured":"Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103:2936\u20138.","journal-title":"Blood"},{"key":"2943_CR10","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","volume":"38","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38:3252\u201360.","journal-title":"J Clin Oncol"},{"key":"2943_CR11","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119:4391\u20134.","journal-title":"Blood"},{"key":"2943_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46\u201358.","journal-title":"N Engl J Med"},{"key":"2943_CR13","doi-asserted-by":"crossref","unstructured":"Muchtar E, Dispenzieri A, Buadi FK, Kapoor P, Dingli D, Kourelis TV, et al. From CyBorD to Dara-CyBorD: ASCT utilization trends in AL amyloidosis, A 15-year analysis. Blood Adv. 2025;9:4311\u20136.","DOI":"10.1182\/bloodadvances.2025016586"},{"key":"2943_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"2943_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612\u20135.","journal-title":"Blood"},{"key":"2943_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ajh.27685","volume":"100","author":"E Muchtar","year":"2025","unstructured":"Muchtar E, Sanchorawala V, Hassan H, Hegenbart U, Schonland S, Lee HC, et al. The impact of melphalan conditioning and CD34 (+) cell dose and schedule on post-transplant outcomes in AL amyloidosis. Am J Hematol. 2025;100:1141\u201351.","journal-title":"Am J Hematol"},{"key":"2943_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130:625\u201331.","journal-title":"Blood"},{"key":"2943_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","volume":"29","author":"V Sanchorawala","year":"2022","unstructured":"Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, et al. Guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2022;29:1\u20137.","journal-title":"Amyloid"},{"key":"2943_CR19","unstructured":"BlueSky Statistics. Chicago, USA: BlueSky Statistics LLC, 2024. Chicago, IL, USA. Available from: https:\/\/www.blueskystatistics.com (2024)."},{"key":"2943_CR20","unstructured":"The Jamovi Project. Jamovi version 2.5; 2024. Sydney, Australia. Available from: https:\/\/www.jamovi.org (2024)."},{"key":"2943_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/bmt.2012.170","volume":"48","author":"MA Gertz","year":"2013","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transpl. 2013;48:557\u201361.","journal-title":"Bone Marrow Transpl"},{"key":"2943_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41409-025-02535-z","volume":"60","author":"E Muchtar","year":"2025","unstructured":"Muchtar E, Dispenzieri A, Sanchorawala V, Hassan H, Mwangi R, Maurer M, et al. A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis. Bone Marrow Transpl. 2025;60:595\u2013602.","journal-title":"Bone Marrow Transpl"},{"key":"2943_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0137-9","volume":"8","author":"R Manwani","year":"2018","unstructured":"Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, et al. Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J. 2018;8:101.","journal-title":"Blood Cancer J"},{"key":"2943_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ajh.24453","volume":"91","author":"YL Hwa","year":"2016","unstructured":"Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016;91:984\u20138.","journal-title":"Am J Hematol"},{"key":"2943_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/13506129.2020.1835635","volume":"28","author":"X Huang","year":"2021","unstructured":"Huang X, Ren G, Chen W, Guo J, Zhao L, Zeng C, et al. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients. Amyloid. 2021;28:75\u201383.","journal-title":"Amyloid"},{"key":"2943_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100092","volume":"2","author":"B Yohannan","year":"2025","unstructured":"Yohannan B, Rees M, Gertz MA, Dispenzieri A, Kapoor P, Buadi FK, et al. Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis. Blood Neoplasia. 2025;2:100092.","journal-title":"Blood Neoplasia"},{"key":"2943_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","volume":"34","author":"E Muchtar","year":"2020","unstructured":"Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, et al. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. 2020;34:1135\u201343.","journal-title":"Leukemia"},{"key":"2943_CR28","doi-asserted-by":"crossref","unstructured":"Tan MS, Warsame R, Parrondo RD, Muchtar E, Kourelis TV, Buadi FK, et al. AL Amyloidosis: a real-world experience with CAR-T cell therapy. Blood Adv. 2025;10:535\u20139.","DOI":"10.1182\/bloodadvances.2025017488"},{"key":"2943_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00950-3","volume":"13","author":"R Chakraborty","year":"2023","unstructured":"Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D\u2019Souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023;13:172.","journal-title":"Blood Cancer J"},{"key":"2943_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00397-w","volume":"11","author":"VJ Premkumar","year":"2021","unstructured":"Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis. Blood Cancer J. 2021;11:10.","journal-title":"Blood Cancer J"},{"key":"2943_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","volume":"36","author":"CA Schiffer","year":"2018","unstructured":"Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36:283\u201399.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02943-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02943-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02943-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:08Z","timestamp":1789119428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02943-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2943"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02943-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VS received research support to the institution from Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, AbbVie, serves as a consultant for Janssen, Eidos\/BridgeBio, Alexion and Pfizer and served on the advisory board for Proclara, Caelum, AbbVie, Janssen, Regeneron, Protego, Pharmatrace, Telix and Prothena. SS: Research support: Janssen, Prothena and Sanofi. Research cooperation: Neurimmune. Advisory boards: Janssen, Telix, Neurimmune and Prothena. Honoraria: AstraZeneca, Alexion, Sobi, Janssen, Takeda, Pfizer and Prothena. Travel and congress participation grants: Janssen, Prothena, Celgene, Binding Site and Jazz. UH received honoraria from Janssen, Pfizer, Alnylam, Prothena, AstraZeneca, received financial support for congress participation from Janssen, Prothena, and Pfizer, serves on advisory Boards for Pfizer, Prothena, Janssen, Alexion, Alnylam and received financial sponsorship of Amyloidosis Registry from Janssen. HCL received research funding from Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithKline, Regeneron, and Takeda Pharmaceuticals and provided consultancy to AbbVie, Bristol Myers Squibb, Janssen, Regeneron, GlaxoSmithKline, Sanofi, Takeda Pharmaceuticals, Allogene Therapeutics, and Pfizer. EJ reports stock ownership in Pfizer, Bristol Myers Squib and Amgen. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. DD serves as a consultant for Alexion, Apellis, Argenyx, Bristol Myers Squibb, Janssen, Novartis, Sanofi, Sorrento and Takeda and research funding from K36 Therapeutics. MM received research funding from Roche\/Genentech, BMS, and GenMab and provided consultancy\/Advisory Board for AstraZeneca and BMS. RC serves as Consultant\/Advisory Board for Janssen, Sanofi, Alexion (AstraZeneca), Adaptive Biotech and received research funding from Genentech, AbbVie. SL serves as Consultant\/Advisory Board for Janssen, Sanofi, Alexion (AstraZeneca), Regeneron, Pfizer, BMS, GSK and received research funding from Sanofi. HL receives research funding from Alexion (AstraZeneca), Nexcella, Janssen, AbbVie, Prothena, Protego and serves as a Consultant\/Advisory board member for Alexion (AstraZeneca), Nexcella, Karyopharm, Arcellx, AbbVie and Pfizer. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. EM received a consultation fee from Protego (a fee paid to the institution). MYM has received research funding and consulting fees from Ossium Health Inc., Bluebird Bio; the remaining authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The Institutional Review Boards approved the study in all the participating centers, IRB #20-11936, with all methods performed in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}